Cargando…
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for th...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017514/ https://www.ncbi.nlm.nih.gov/pubmed/29498635 http://dx.doi.org/10.3390/molecules23030551 |